Enliven Therapeutics

Global cancer cases surge, with a 79% rise in new cases among patients under 50. The highest death tolls are linked to breast, windpipe, lung, bowel, and stomach cancers. Cancer rates are projected to increase by 77% by 2050. In response, biotech firms like Oncolytics, AbbVie, BeiGene, HUTCHMED, and Enliven Therapeutics are accelerating treatment innovations, with the FDA approving 16 new oncology treatments in 2024. Oncolytics plans to submit a clinical trial for breast cancer treatment to the FDA in early 2025.

Cancer rates are surging globally, especially among patients under 50, with a 79% rise in new cases. The United Nations predicts a 77% increase by 2050. In response, the FDA has approved 16 new oncology treatments between July and September 2024. Oncolytics Biotech Inc. is making significant progress with its immunotherapeutic agent, pelareorep, in breast and pancreatic cancer treatments, aiming for FDA accelerated approval. The global oncology drug market is expected to grow at a CAGR of 11.5% to reach $564.50 billion by 2033, while the AI in oncology market is growing at a 35% CAGR.

ELVN-001 Phase 1 trial shows 44% cumulative MMR rate by 24 weeks in heavily pretreated CML patients, with stable or deepening responses and good tolerability.